B.S.: Washington State University, Pullman, WA, 1980.
Ph.D.: Purdue University, W. Lafayette, IN, 1984.
Postdoctoral Fellowship: Yale University, New Haven, CT, 1985-1987.
Dr. Sebti's lab's research interests are focused on understanding the mechanisms by which aberrant signal transduction pathways contribute to oncogenesis and developing novel anticancer drugs based on interfering with these pathways. Among the pathways studied are those involving the Ras superfamily (Ras, Rho and Ral), Kinases (Akt, RhoK and Aurora), STAT3, Bcl/Mcl, FTase/GGTase and the proteasome. In 2016, Dr. Sebti was awarded an Outstanding Investigator Award from the National Cancer Institute (NCI). The prestigious award, which provides grant funding over a seven year term, is given to well-established cancer researchers with proven track records to encourage long-term projects of unusual potential in cancer research. Dr. Sebti’s award totals $6,415,284 million. Dr. Sebti will use the funds to further his research on novel drug therapies for KRas-mutated cancers. The proposed research is highly significant, is of high priority, and has long-term relevance to NCI’s mission. With mt KRas significantly contributing to human oncogenesis and patient tumor resistance to therapy, and no anticancer drugs targeting mt KRas yet available in clinic, the NCI identified targeting Ras as a high priority and has implemented a major initiative with the ultimate goal of discovering therapies that specifically target patients whose tumors harbor mt Ras. This Outstanding Investigator Award will engage in research that tackles this challenging problem on many fronts.